Skip to content
OpenCapital
Get started

Protagonist Therapeutics PTGX Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$359M+63.2%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0×0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's proceeds from sale and maturity of available for sale securities?
Protagonist Therapeutics (PTGX) reported proceeds from sale and maturity of available for sale securities of $156.69M in Q1 2026.
How has Protagonist Therapeutics's proceeds from sale and maturity of available for sale securities changed year-over-year?
Protagonist Therapeutics's proceeds from sale and maturity of available for sale securities increased by 38.4% year-over-year, from $113.18M to $156.69M.
What is the long-term trend for Protagonist Therapeutics's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Protagonist Therapeutics's proceeds from sale and maturity of available for sale securities has grown at a 16.0% compound annual growth rate (CAGR), from $271.83M to $491.84M.